Nanjing Triastek Medical Technology and BioNTech Strike Landmark $1.2 Billion Global Drug Delivery Collaboration

In the wave of innovative technology, a leading company in China has once again demonstrated its leading position in the field of pharmaceutical technology. On July 23, 2024, Nanjing Triastek Medical Technology Limited Company, a pioneer in 3D printing drug manufacturing, Announced the establishment of an in-depth research collaboration and platform technology license agreement with BioNTech SE, a global next-generation immunotherapy giant. The conclusion of this cooperation indicates that the global pharmaceutical industry is about to usher in a revolutionary change.

Under the agreement, Triastek will leverage its advanced 3D printed drug technology to jointly develop innovative oral RNA therapies with BioNTech aimed at addressing an unmet need in current clinical therapies. Triastek has received $10 million in initial funding from this partnership, along with the prospect of more than $1.2 billion in milestone payments and future tiered sales royalties depending on the development and commercialization process, which is undoubtedly a strong recognition of the value of Triastek's technology.

Triastek's founder and CEO commented, "We are honored to partner with an industry leader like BioNTech who is transforming patients' lives with innovative treatments. We strongly believe that this collaboration will open a new chapter in 3D printing technology in oral RNA drug development and set a new standard for oral delivery of macromolecular drugs."

Triastek's 3D printing technology is known for its unique precision control ability to precisely control the timing, location and rate of drug release, providing unprecedented flexibility to meet diverse clinical needs. In this collaboration, Triastek will take advantage of this technology to optimize the efficiency and safety of RNA drug delivery in the gastrointestinal tract, with a view to achieving more efficient and safer therapeutic outcomes.

This cooperation not only created the record of the highest cooperation amount in the world in the field of drug delivery, but also marked a major breakthrough in China's pharmaceutical preparation technology on the global stage. As more and more Chinese innovative biotechnology companies cooperate with international giants in depth, China's pharmaceutical industry is integrating into the global innovation network at an unprecedented speed, showing strong innovation capabilities and international competitiveness.